Ocata Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

OCAT 7.10 -0.38 (-5.08%)
price chart
The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics ...
Ocata Therapeutics has entered an optimal moment in its developmental life cycle to initiate a long position. Prior to the as yet unknown date of up-list to the NASDAQ, which will occur with an accompanying equity raise, there is reason to believe the ...
Latest Updates on Ocata Therapeutics Inc (OTCMKTS:OCAT)  Equities Focus (registration)
Should You Purchase Ocata Therapeutics Inc(OCAT), Mitsubishi Estate Co Ltd ...  NIS
Related articles »  
Ocata Therapeutics Licenses Induced Pluripotent Stem Cell Technology from ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (�Ocata� or �the Company�; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology�, today announced that it has entered into a definitive agreement with Allele ...
Ocata Therapeutics licenses induced pluripotent stem cell (iPSC) technology ...  European Pharmaceutical Review
Ocata Therapeutics (OCAT) Enters iPSC Licensing Agreement with Allele Biotech  StreetInsider.com
Advanced Cell Technology Changes Name to Ocata Therapeutics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's ...
Related articles »  
Should you place a bet on Ocata Therapeutics?
This brings us to Ocata Therapeutics. The company calls itself a "leader in regenerative medicine." What is that, and on what basis is Advanced Cell a leader in this field?
Related articles »  
Ocata Therapeutics To Trade On Nasdaq Global Market: Can The Bulls Finally ...
After months, if not years for some, Ocata shareholders were pleasantly surprised by the after-hours filing of the Form 8-A on February 23, 2015 by Ocata Therapeutics (NASDAQ:OCAT), which provides for registration of certain classes of securities ...
Ocata Therapeutics Inc (OTCMKTS:OCAT) Is Rewarded With Two New Immune ...  Traders350
Ocata Therapeutics Approved for Listing on NASDAQ  PharmiWeb.com (press release)
Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
MARLBOROUGH, Mass., Mar 31, 2015 (BUSINESS WIRE) -- Ocata Therapeutics, Inc. (�Ocata�; NASDAQ:OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has completed dosing of its Phase 1/2 studies for dry ...
Form SC 13G/A Ocata Therapeutics, Inc. Filed by: Aronson Gary D
Check the appropriate box to designate the Rule pursuant to which this Schedule is filed. �, Rule 13d-1(b). x, Rule 13d-1(c). �, Rule 13d-1(d).
Ocata Therapeutics, Inc. Files SEC Form SC 13G, Statement of Acquisition of ...
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Ocata Therapeutics Receives Regulatory Guidance from European Medicines ...
Ocata Therapeutics, Inc. (�Ocata�; NASDAQ: OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has received written formal guidance from the European Medicines Agency (EMA) related to the advancement of its ...
Advanced Cell Technology's Turnaround Has Near-Term Catalysts (ACTC)
When Paul Wotton decided to leave a secure high paying CEO position at Antares Pharma to come aboard a financially strapped company with a history of bad financing decisions it was a turning point at ACT (soon to be known as Ocata Therapeutics).